B+
Bull case
25%
Probability
Target price
$500.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
HCA
HCA HealthcareBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$455.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$350.00
Analysis reference price unavailable
Analysis 2026-08-05 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-05
Recent news sentiment (30D)
+58.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+67.6
Score
AI commentary
News tone is mixed-positive: Q2 operating results and volume trends were favorable, but coverage has emphasized uninsured-patient growth, payer-mix pressure, and weaker elective surgery. Social, options, short-interest, employee-review, and direct analyst-revision data were unavailable, limiting conviction despite strong primary filing coverage.
RankAlpha Sentiment Codex - 2026-08-05
Open full AI memoEvidence flagged
high-coverage report lacks a dated company-specific catalyst beyond generic cadence
Impact
tentative
Confidence
-
AI events
2026-11-03eventPayer-mix and Medicaid-payment follow-throughMedium impact
Florida directed-payment approval contributed approximately $400 million of incremental net benefit in Q2, while uninsured volume created an approximately $400 million pretax payer-mix headwind; the balance of these effects is the key 2026-H2 monitoring item. [#SEC-8K-2026-07-24]
2026-11-03catalystQ2 print and 2026 guidance resetMedium impact
HCA previewed Q2 results and revised 2026 guidance on July 14, then confirmed Q2 revenue of $20.230 billion, diluted EPS of $7.62, adjusted EBITDA of $4.027 billion, and same-facility admissions growth of 2.5% on July 24. [#SEC-8K-2026-07-14] [#SEC-8K-2026-07-24]
2027-08-05catalystSustained hospital volume and pricing growthHigh impact
Q2 same-facility equivalent admissions rose 2.7%, emergency-room visits rose 3.6%, and revenue per equivalent admission rose 6.4%; durability of these trends could support earnings resilience. [#SEC-8K-2026-07-24]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-05 • Updated nightlySource: Internal modelMethodology